Patent Grant
11938058
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present disclosure pertains generally, but not by way of limitation, to medical devices, and methods for manufacturing medical devices. The present invention relates generally to devices that are implanted within the eye. More particularly, the present invention relates to devices that facilitate the transfer of fluid from within one area of the eye to another area of the eye. Additionally, the present disclosure relates to systems, devices and methods for delivering ocular implants into the eye.
According to a draft report by The National Eye Institute (NEI) at The United States National Institutes of Health (NIH), glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world. Thus, the NEI draft report concludes, “it is critical that significant emphasis and resources continue to be devoted to determining the pathophysiology and management of this disease.” Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma. For this reason, eye care professionals routinely screen patients for glaucoma by measuring intraocular pressure using a device known as a tonometer. Many modern tonometers make this measurement by blowing a sudden puff of air against the outer surface of the eye.
The eye can be conceptualized as a ball filled with fluid. There are two types of fluid inside the eye. The cavity behind the lens is filled with a viscous fluid known as vitreous humor. The cavities in front of the lens are filled with a fluid know as aqueous humor. Whenever a person views an object, he or she is viewing that object through both the vitreous humor and the aqueous humor.
Whenever a person views an object, he or she is also viewing that object through the cornea and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the anterior chamber of the eye through the trabecular meshwork and into Schlemm's canal as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the venous blood stream from Schlemm's canal and is carried along with the venous blood leaving the eye.
When the natural drainage mechanisms of the eye stop functioning properly, the pressure inside the eye begins to rise. Researchers have theorized prolonged exposure to high intraocular pressure causes damage to the optic nerve that transmits sensory information from the eye to the brain. This damage to the optic nerve results in loss of peripheral vision. As glaucoma progresses, more and more of the visual field is lost until the patient is completely blind.
In addition to drug treatments, a variety of surgical treatments for glaucoma have been performed. For example, shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Opthalmology (February 1966)). Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. Nos. 4,968,296 and 5,180,362). Still others were shunts leading from the anterior chamber to a point just inside Schlemm's canal (Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?” Ophthalmic Surgery and Lasers (June 1999); U.S. Pat. Nos. 6,450,984; 6,450,984).
The invention provides design, material, and manufacturing method alternatives for medical devices.
An illustrative method for reducing intraocular pressure in a patient may comprise deploying an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye and administering a therapeutic agent comprising a Rho kinase (ROCK) inhibitor to the patient. The implant may comprise a tubular body having an inner surface and an outer surface. The tubular body may extend in a curved volume whose longitudinal axis forms an arc of a circle. A plurality of open areas and strut areas may be formed in the tubular body and the strut areas may surround the plurality of open areas. The tubular body may have a diameter of between 0.005 inches and 0.04 inches. The ocular implant may be configured to lower the intraocular pressure from an initial to a second pressure within a first range and the therapeutic agent may lower an intraocular pressure to a third pressure within a second range, the third pressure lower than the second pressure.
In another illustrative embodiment a kit for reducing intraocular pressure in a patient may be provided. The kit may comprise an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, a cannula defining a passageway extending from a proximal end to a distal end, a delivery tool having a distal interlocking portion engaging a complementary interlocking portion of the ocular implant, and a therapeutic agent comprising a Rho kinase (ROCK) inhibitor. The cannula may have a distal opening extending through a side wall and the distal end of the cannula to form a trough, a curved distal portion, a curved intermediate portion, and a proximal portion.
The above summary of some examples and embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Brief Description of the Drawings, and Detailed Description, which follow, more particularly exemplify these embodiments, but are also intended as exemplary and not limiting.
In one embodiment, a method for reducing intraocular pressure in a patient is provided, the method comprising deploying an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, the implant comprising, a tubular body having an inner surface and an outer surface, the tubular body extending in a curved volume whose longitudinal axis forms an arc of a circle, and a plurality of open areas and strut areas formed in the tubular body, the strut areas surrounding the plurality of open areas, and the tubular body having a diameter of between 0.005 inches and 0.04 inches, wherein the ocular implant is configured to lower the intraocular pressure from an initial to a second pressure within a first range, and administering a therapeutic agent comprising a Rho kinase (ROCK) inhibitor to the patient to lower an intraocular pressure to a third pressure within a second range, the third pressure lower than the second pressure.
In some embodiments, deploying the ocular implant comprises inserting a distal end of a cannula through an incision in the eye and into an anterior chamber of the eye, placing the distal opening of the cannula into fluid communication with Schlemm's canal such that the cannula enters Schlemm's canal in a substantially tangential orientation, advancing the ocular implant distally through the cannula with a delivery tool engaged with the ocular implant, a proximal portion of the ocular implant engaging the delivery tool proximal to a distal portion of the delivery tool, and disengaging the ocular implant and the delivery tool when the proximal portion of the ocular implant reaches distal opening of the cannula.
In some embodiments, the first range is approximately 20 to 30 mm Hg. In other embodiments, the first range is approximately 23 to 28 mm Hg. In other embodiments, the second range is approximately 13 to 23 mm Hg. In some embodiments, the second range is approximately 15 to 20 mm Hg.
In one embodiment, the implant further comprises a first pressure sensor disposed on the inner surface of the tubular body.
A method for reducing intraocular pressure in a patient is also provided, the method comprising, deploying an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, the implant comprising a tubular body having an inner surface and an outer surface, the tubular body extending in a curved volume whose longitudinal axis forms an arc of a circle, and a plurality of open areas and strut areas formed in the tubular body, the strut areas surrounding the plurality of open areas, and the tubular body having a diameter of between 0.005 inches and 0.04 inches, wherein the ocular implant is configured to lower the intraocular pressure to a second pressure less than the initial pressure, and administering a therapeutic agent comprising a Rho kinase (ROCK) inhibitor to the patient to lower an intraocular pressure from an initial to a third pressure, the third pressure less than the second pressure.
In one embodiment, deploying the ocular implant comprises inserting a distal end of a cannula through an incision in the eye and into an anterior chamber of the eye, placing the distal opening of the cannula into fluid communication with Schlemm's canal such that the cannula enters Schlemm's canal in a substantially tangential orientation, advancing the ocular implant distally through the cannula with a delivery tool engaged with the ocular implant, a proximal portion of the ocular implant engaging the delivery tool proximal to a distal portion of the delivery tool, and disengaging the ocular implant and the delivery tool when the proximal portion of the ocular implant reaches distal opening of the cannula.
In some embodiments, the second pressure is approximately 65 to 95% of the initial pressure. In another embodiment, the second pressure is approximately 75 to 85% of the initial pressure.
In one embodiment, the third pressure is approximately 65 to 95% of the second pressure. In another embodiment, the third pressure is approximately 75 to 85% of the second pressure.
In some embodiments, the implant further comprises a first pressure sensor disposed on the inner surface of the tubular body.
A kit for reducing intraocular pressure in a patient is provided, the kit comprising, an ocular implant adapted to reside at least partially in a portion of Schlemm's canal of an eye, a cannula defining a passageway extending from a proximal end to a distal end, the cannula having a distal opening extending through a side wall and the distal end of the cannula to form a trough, a curved distal portion, a curved intermediate portion, and a proximal portion, and a delivery tool having a distal interlocking portion engaging a complementary interlocking portion of the ocular implant, a therapeutic agent comprising a Rho kinase (ROCK) inhibitor.
In one embodiment, the kit further comprises a therapeutic agent delivery device.
In another embodiment, the therapeutic agent delivery device comprises an eye dropper.
In some embodiments, the ocular implant comprises a tubular body having an inner surface and an outer surface, the tubular body extending in a curved volume whose longitudinal axis forms an arc of a circle, and a plurality of open areas and strut areas formed in the tubular body, the strut areas surrounding the plurality of open areas, and the tubular body having a diameter of between 0.005 inches and 0.04 inches.
In one embodiment, the ocular implant further comprises a first pressure sensor disposed on the inner surface of the tubular body.
In another embodiment, the therapeutic agent is disposed on a surface of the ocular implant.
The disclosure may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:
While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed invention. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed invention.
Definitions of certain terms are provided below and shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same or substantially the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (i.e., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include or otherwise refer to singular as well as plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed to include “and/or,” unless the content clearly dictates otherwise.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or able to be arranged with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
The following detailed description should be read with reference to the drawings, in which similar elements in different drawings are identified with the same reference numbers. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.
Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
In a healthy eye, aqueous humor flows out of the anterior chamber 30 through the trabecular meshwork 36 and into Schlemm's canal 38, located at the outer edge of the iris 42. Aqueous humor exits Schlemm's canal 38 by flowing through a number of outlets 40. After leaving Schlemm's canal 38, aqueous humor is absorbed into the venous blood stream.
In
Ocular implant 100 may be inserted into Schlemm's canal of a human eye to facilitate the flow of aqueous humor out of the anterior chamber. This flow may include axial flow along Schlemm's canal, flow from the anterior chamber into Schlemm's canal, and flow leaving Schlemm's canal via outlets communicating with Schlemm's canal. When in place within the eye, ocular implant 100 will support trabecular mesh tissue and Schlemm's canal tissue and will provide for improved communication between the anterior chamber and Schlemm's canal (via the trabecular meshwork) and between pockets or compartments along Schlemm's canal. As shown in
The frames 104 of body 102 include a first frame 136 of ocular implant 100 that is disposed between a first spine 140 and a second spine 142. In the embodiment of
In the embodiment of
In some instances, the ocular implant 100 may further include a coating 129 disposed on the inner surfaces 128 and/or outer surfaces 127 of the implant 100, as shown in
The coating 129 may be formed of, or otherwise include, a therapeutic agent. In some embodiments, the coating 129 may release the therapeutic agent. The coating 129 may release the therapeutic agent controllably over a period of time. In some embodiments, the therapeutic agent may be applied directly to the ocular implant 100 while in other embodiments, the ocular implant may be dispersed within a matrix material. For example, the therapeutic agent may be dispersed within a biocompatible or biodegradable polymeric material. The concentration of therapeutic agent within the matrix material may vary depending on the desired treatment.
The biocompatible polymeric material used to form the bioactive agent-polymer composite layer(s) may include any polymeric material capable of forming a solidified composite layer in the presence of the bioactive material. The polymeric material of the present invention may be hydrophilic or hydrophobic, and is, for example, polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, polyolefins, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof as well as other biodegradable, bioabsorbable and biostable polymers and copolymers. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention. The polymer may be a protein polymer, fibrin, collagen and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example. The coating 129 can include of a single polymer or copolymer. The coating 129 may also include copolymers or physical blends of any of the materials indicated above.
The therapeutic agents utilized with the ocular implant, may include one or more drugs provided below, either alone or in combination. The drugs utilized may also be the equivalent of, derivatives of, or analogs of one or more of the drugs provided below. The drugs may include but are not limited to pharmaceutical agents including anti-glaucoma medications, ocular agents, antimicrobial agents (e.g., antibiotic, antiviral, antiparasitic, antifungal agents), anti-inflammatory agents (including steroids or non-steroidal anti-inflammatory), biological agents including hormones, enzymes or enzyme-related components, antibodies or antibody-related components, oligonucleotides (including DNA, RNA, short-interfering RNA, antisense oligonucleotides, and the like), DNA/RNA vectors, viruses (either wild type or genetically modified) or viral vectors, peptides, proteins, enzymes, extracellular matrix components, and live cells configured to produce one or more biological components. The use of any particular drug is not limited to its primary effect or regulatory body-approved treatment indication or manner of use. Drugs also include compounds or other materials that reduce or treat one or more side effects of another drug or therapeutic agent. As many drugs have more than a single mode of action, the listing of any particular drug within any one therapeutic class below is only representative of one possible use of the drug and is not intended to limit the scope of its use with the ophthalmic implant system.
The therapeutic agents may be combined with any number of excipients as is known in the art. In addition to the biodegradable polymeric excipients discussed above, other excipients may be used, including, but not limited to, benzyl alcohol, ethylcellulose, methylcellulose, hydroxymethylcellulose, cetyl alcohol, croscarmellose sodium, dextrans, dextrose, fructose, gelatin, glycerin, monoglycerides, diglycerides, kaolin, calcium chloride, lactose, lactose monohydrate, maltodextrins, polysorbates, pregelatinized starch, calcium stearate, magnesium stearate, silcon dioxide, cornstarch, talc, and the like. The one or more excipients may be included in total amounts as low as about 1%, 5%, or 10% and in other embodiments may be included in total amounts as high as 50%, 70% or 90%.
Examples of drugs may include various anti-secretory agents; antimitotics and other anti-proliferative agents, including among others, anti-angiogenesis agents such as angiostatin, anecortave acetate, thrombospondin, VEGF receptor tyrosine kinase inhibitors and anti-vascular endothelial growth factor (anti-VEGF) drugs such as ranibizumab (LUCENTIS®) and bevacizumab (AVASTIN®), pegaptanib (MACUGEN®) sunitinib and sorafenib and any of a variety of known small-molecule and transcription inhibitors having anti-angiogenesis effect; classes of known ophthalmic drugs, including: glaucoma agents, such as adrenergic antagonists, including for example, beta-blocker agents such as atenolol propranolol, metipranolol, betaxolol, betaxolol hydrochloride carteolol, levobetaxolol, levobunolol, levobunolol hydrochloride, timolol, timolol hemihydrate, and timolol maleate; adrenergic agonists or sympathomimetic agents such as epinephrine, dipivefrin, clonidine, aparclonidine, and brimonidine; parasympathomimetics or cholingeric agonists such as pilocarpine, carbachol, phospholine iodine, and physostigmine, salicylate, acetylcholine chloride, eserine, diisopropyl fluorophosphate, demecarium bromide); muscarinics; carbonic anhydrase inhibitor agents, including topical and/or systemic agents, for example acetozolamide, brinzolamide, dorzolamide and methazolamide, ethoxzolamide, diamox, and dichlorphenamide; mydriatic-cycloplegic agents such as atropine, cyclopentolate, succinylcholine, homatropine, phenylephrine, scopolamine and tropicamide; prostaglandins such as prostaglandin F2 alpha, antiprostaglandins, prostaglandin precursors, or prostaglandin analog agents such as bimatoprost, latanoprost, travoprost, tafluprost and unoprostone; docosanoid compounds such as unoprostone.
Other examples of drugs may also include anti-inflammatory agents including for example glucocorticoids and corticosteroids such as betamethasone, cortisone, dexamethasone, dexamethasone 21-phosphate, methylprednisolone, prednisolone 21-phosphate, prednisolone acetate, prednisolone, fluroometholone, loteprednol, medrysone, fluocinolone acetonide, triamcinolone acetonide, triamcinolone, triamcinolone acetonide, beclomethasone, budesonide, flunisolide, fluorometholone, fluticasone, hydrocortisone, hydrocortisone acetate, loteprednol, rimexolone and non-steroidal anti-inflammatory agents including, for example, diclofenac, flurbiprofen, ibuprofen, bromfenac, nepafenac, and ketorolac, salicylate, indomethacin, ibuprofen, naxopren, piroxicam and nabumetone; anti-infective or antimicrobial agents such as antibiotics including, for example, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, cephalexin, oxytetracycline, chloramphenicol, rifampicin, ciprofloxacin, tobramycin, gentamycin, erythromycin, penicillin, sulfonamides, sulfadiazine, sulfacetamide, sulfamethizole, sulfisoxazole, nitrofurazone, sodium propionate, aminoglycosides such as gentamicin and tobramycin; fluoroquinolones such as ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin; bacitracin, erythromycin, fusidic acid, neomycin, polymyxin B, gramicidin, trimethoprim and sulfacetamide; antifungals such as amphotericin B and miconazole; antivirals such as idoxuridine trifluorothymidine, acyclovir, gancyclovir, interferon; antimicotics; immune-modulating agents such as antiallergenics, including, for example, sodium chromoglycate, antazoline, methapyriline, chlorpheniramine, cetrizine, pyrilamine, prophenpyridamine anti-histamine agents such as azelastine, emedastine and levocabastine; immunological drugs (such as vaccines and immune stimulants); MAST cell stabilizer agents such as cromolyn sodium, ketotifen, lodoxamide, nedocrimil, olopatadine and pemirolastciliary body ablative agents, such as gentimicin and cidofovir; and other ophthalmic agents such as verteporfin, proparacaine, tetracaine, cyclosporine and pilocarpine; inhibitors of cell-surface glycoprotein receptors; decongestants such as phenylephrine, naphazoline, tetrahydrazoline; lipids or hypotensive lipids; dopaminergic agonists and/or antagonists such as quinpirole, fenoldopam, and ibopamine; vasospasm inhibitors; vasodilators; antihypertensive agents; angiotensin converting enzyme (ACE) inhibitors; angiotensin-1 receptor antagonists such as olmesartan; microtubule inhibitors; molecular motor (dynein and/or kinesin) inhibitors; actin cytoskeleton regulatory agents such as cyctchalasin, latrunculin, swinholide A, ethacrynic acid, H-7, and Rho-kinase (ROCK) inhibitors; remodeling inhibitors; modulators of the extracellular matrix such as tert-butylhydro-quinolone and AL-3037A; adenosine receptor agonists and/or antagonists such as dicyanopyridines, N-6-cylclophexyladenosine and (R)-phenylisopropyladenosine; serotonin agonists; hormonal agents such as estrogens, estradiol, progestational hormones, progesterone, insulin, calcitonin, parathyroid hormone, peptide and vasopressin hypothalamus releasing factor; growth factor antagonists or growth factors, including, for example, epidermal growth factor, fibroblast growth factor, platelet derived growth factor, transforming growth factor beta, somatotrapin, fibronectin, connective tissue growth factor, bone morphogenic proteins (BMPs); cytokines such as interleukins, CD44, cochlin, and serum amyloids, such as serum amyloid A.
Other therapeutic agents may include neuroprotective agents such as lubezole, nimodipine and related compounds, and including blood flow enhancers, sodium channels blockers, glutamate inhibitors such as memantine, neurotrophic factors, nitric oxide synthase inhibitors; free radical scavengers or anti-oxidants; chelating compounds; apoptosis-related protease inhibitors; compounds that reduce new protein synthesis; radiotherapeutic agents; photodynamic therapy agents; gene therapy agents; genetic modulators; and dry eye medications such as cyclosporine A, delmulcents, and sodium hyaluronate.
Other therapeutic agents that may be used include: other beta-blocker agents such as acebutolol, atenolol, bisoprolol, carvedilol, asmolol, labetalol, nadolol, penbutolol, and pindolol; other corticosteroidal and non-steroidal anti-inflammatory agents such aspirin, betamethasone, cortisone, diflunisal, etodolac, fenoprofen, fludrocortisone, flurbiprofen, hydrocortisone, ibuprofen, indomethacine, ketoprofen, meclofenamate, mefenamic acid, meloxicam, methylprednisolone, nabumetone, naproxen, oxaprozin, prednisolone, prioxicam, salsalate, sulindac and tolmetin; COX-2 inhibitors like celecoxib, rofecoxib and Valdecoxib; other immune-modulating agents such as aldesleukin, adalimumab (HUMIRA®), azathioprine, basiliximab, daclizumab, etanercept (ENBREL®), hydroxychloroquine, infliximab (REMICADE®), leflunomide, methotrexate, mycophenolate mofetil, and sulfasalazine; other anti-histamine agents such as loratadine, desloratadine, cetirizine, diphenhydramine, chlorpheniramine, dexchlorpheniramine, clemastine, cyproheptadine, fexofenadine, hydroxyzine and promethazine; other anti-infective agents such as aminoglycosides such as amikacin and streptomycin; anti-fungal agents such as amphotericin B, caspofungin, clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole, terbinafine and nystatin; anti-malarial agents such as chloroquine, atovaquone, mefloquine, primaquine, quinidine and quinine; anti-mycobacterium agents such as ethambutol, isoniazid, pyrazinamide, rifampin and rifabutin; anti-parasitic agents such as albendazole, mebendazole, thiobendazole, metronidazole, pyrantel, atovaquone, iodoquinaol, ivermectin, paromycin, praziquantel, and trimatrexate; other anti-viral agents, including anti-CMV or anti-herpetic agents such as acyclovir, cidofovir, famciclovir, gangciclovir, valacyclovir, valganciclovir, vidarabine, trifluridine and foscarnet; protease inhibitors such as ritonavir, saquinavir, lopinavir, indinavir, atazanavir, amprenavir and nelfinavir; nucleotide/nucleoside/non-nucleoside reverse transcriptase inhibitors such as abacavir, ddl, 3TC, d4T, ddC, tenofovir and emtricitabine, delavirdine, efavirenz and nevirapine; other anti-viral agents such as interferons, ribavirin and trifluridiene; other anti-bacterial agents, including cabapenems like ertapenem, imipenem and meropenem; cephalosporins such as cefadroxil, cefazolin, cefdinir, cefditoren, cephalexin, cefaclor, cefepime, cefoperazone, cefotaxime, cefotetan, cefoxitin, cefpodoxime, cefprozil, ceftaxidime, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime and loracarbef; other macrolides and ketolides such as azithromycin, clarithromycin, dirithromycin and telithromycin; penicillins (with and without clavulanate) including amoxicillin, ampicillin, pivampicillin, dicloxacillin, nafcillin, oxacillin, piperacillin, and ticarcillin; tetracyclines such as doxycycline, minocycline and tetracycline; other anti-bacterials such as aztreonam, chloramphenicol, clindamycin, linezolid, nitrofurantoin and vancomycin; alpha blocker agents such as doxazosin, prazosin and terazosin; calcium-channel blockers such as amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine and verapamil; other anti-hypertensive agents such as clonidine, diazoxide, fenoldopan, hydralazine, minoxidil, nitroprusside, phenoxybenzamine, epoprostenol, tolazoline, treprostinil and nitrate-based agents; anti-coagulant agents, including heparins and heparinoids such as heparin, dalteparin, enoxaparin, tinzaparin and fondaparinux; other anti-coagulant agents such as hirudin, aprotinin, argatroban, bivalirudin, desirudin, lepirudin, warfarin and ximelagatran; anti-platelet agents such as abciximab, clopidogrel, dipyridamole, optifibatide, ticlopidine and tirofiban; prostaglandin PDE-5 inhibitors and other prostaglandin agents such as alprostadil, carboprost, sildenafil, tadalafil and vardenafil; thrombin inhibitors; antithrombogenic agents; anti-platelet aggregating agents; thrombolytic agents and/or fibrinolytic agents such as alteplase, anistreplase, reteplase, streptokinase, tenecteplase and urokinase; anti-proliferative agents such as sirolimus, tacrolimus, everolimus, zotarolimus, paclitaxel and mycophenolic acid; hormonal-related agents including levothyroxine, fluoxymestrone, methyltestosterone, nandrolone, oxandrolone, testosterone, estradiol, estrone, estropipate, clomiphene, gonadotropins, hydroxyprogesterone, levonorgestrel, medroxyprogesterone, megestrol, mifepristone, norethindrone, oxytocin, progesterone, raloxifene and tamoxifen; anti-neoplastic agents, including alkylating agents such as carmustine lomustine, melphalan, cisplatin, fluorouracil3, and procarbazine antibiotic-like agents such as bleomycin, daunorubicin, doxorubicin, idarubicin, mitomycin and plicamycin; anti proliferative agents (such as 1,3-cis retinoic acid, 5-fluorouracil, taxol, rapamycin, mitomycin C and cisplatin); antimetabolite agents such as cytarabine, fludarabine, hydroxyurea, mercaptopurine and 5-flurouracil (5-FU); immune modulating agents such as aldesleukin, imatinib, rituximab and tositumomab; mitotic inhibitors docetaxel, etoposide, vinblastine and vincristine; radioactive agents such as strontium-89; and other anti-neoplastic agents such as irinotecan, topotecan and mitotane.
In the embodiment of
Stated another way, in the embodiment of
An inner surface 128 of body 102 defines a channel 126. Body 102 of ocular implant 100 includes a first edge 120 and a second edge 123 that define a first opening 124. Channel 126 of ocular implant 100 fluidly communicates with first opening 124. A second opening 138 is defined by a second edge 122A of a first strut 144 and a second edge 122B of a second strut 146. First opening 124, second opening 138 and additional openings defined by ocular implant 100 allow aqueous humor to flow laterally across and/or laterally through ocular implant 100.
As shown in
In the embodiment of
In
The geometry of the spine provides the ocular implant with flexibility characteristics that may aid in advancing the ocular implant into Schlemm's canal. In the embodiment of
In some useful embodiments, the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W1 to thickness T1 greater than about 2. In some particularly useful embodiments, the spine of an ocular implant in accordance with this detailed description has an aspect ratio of width W1 to thickness T1 greater than about 4. In one useful embodiment, the ocular implant has a spine with an aspect ratio of width W1 to thickness T1 of about 5.2.
A first axis 156, a second axis 158 and a third axis 160 are shown in
In the embodiment of
In the embodiment of
Each strut shown in
In the embodiment of
In some useful embodiments, the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W2 to thickness T2 greater than about 2. In some particularly useful embodiments, the struts of an ocular implant in accordance with this detailed description have an aspect ratio of width W2 to thickness T2 greater than about 4. One exemplary ocular implant has struts with an aspect ratio of width W2 to thickness T2 of about 4.4.
Body 102 of ocular implant 100 has a longitudinal radius 150 and a lateral radius 148. In some useful embodiments, an ocular implant in accordance with this detailed description is sufficiently flexible to assume a shape matching the longitudinal curvature of Schlemm's canal when the ocular implant advanced into the eye. Also in some useful embodiments, a length of the ocular implant is selected so that the implant will extend across a pre-selected angular span when the implant is positioned in Schlemm's canal. Examples of pre-selected angular spans that may be suitable in some applications include 60°, 90°, 150° and 180°. The diameter of an ocular implant in accordance with this detailed description may be selected so that the ocular implant is dimensioned to lie within and support Schlemm's canal. In some useful embodiments, the diameter of the ocular implant ranges between about 0.005 inches (0.127 millimeters) and about 0.04 inches (1.016 millimeters). In some particularly useful embodiments, the diameter of the ocular implant ranges between about 0.005 inches (0.127 millimeters) and about 0.02 inches (0.508 millimeters).
It is to be appreciated that an ocular implant in accordance with the present detailed description may be straight or curved. If the ocular implant is curved, it may have a substantially uniform longitudinal radius throughout its length, or the longitudinal radius of the ocular implant may vary along its length.
The pressure sensor 180 may be a Micro-Electro-Mechanical System (MEMS) pressure sensor. While the pressure sensor 180 has been described as a MEMS pressure sensor, it is contemplated that other pressure sensors may be used in place of, or in addition to, a MEMS pressure sensor. In some instances, the pressure sensor 180 may have a width in the range of approximately 0.02 millimeters (20 micrometers) to approximately 1.0 millimeters. However, it is contemplated that the pressure sensors 180 are smaller than 20 micrometers, or larger than 1.0 millimeter. In some instances, the pressure sensor 180 may have a width dimension in the nanometer range. Further, while only a single pressure sensor 180 has been illustrated, the ocular implant 100 may include more than one pressure sensor 180, as desired. For example, a first pressure sensor may be placed at a first end of the ocular implant 100 and a second pressure sensor may be placed at a second end of the ocular implant. In some instances, the pressure sensor 180 may be provided in the channel 128 adjacent to the proximal end 101 of the implant 100, as shown in
MEMS pressure sensors are often formed by anisotropically etching a recess into a back side of a silicon substrate die, leaving a thin flexible diaphragm 182. In operation, at least one surface of the diaphragm 182 is exposed to an input pressure (e.g., the ocular pressure). The diaphragm 182 deflects according to the magnitude of the input pressure, which may be detected by one or more electrical components or sense elements 186 (e.g., piezoresistors) positioned on or embedded within the diaphragm 182. The change in resistance of the piezoresistors 186 is reflected as a change in an output voltage signal from a resistive bridge formed at least in part by the piezoresistors. In some cases, the diaphragm may be made thinner with the addition of support bosses, which may help increase the sensitivity of the diaphragm over a flat plate diaphragm. Circuit elements may be connected so that sensor elements 186 to provide some level of signal processing before providing an output signal to bond pads 188 of the pressure sensor 180. The signal processing may filter, amplify, linearize, calibrate and/or otherwise process the raw sensor signal produced by the sensor elements (e.g., piezoresistors 186). While the sense elements 186 have been described as piezoresistors, it is contemplated that the sense elements may be selected to provide a capacitive pressure sensor 180.
The pressure sensor 180 may include a first substrate 185 and a second substrate 183, as shown in
The second substrate 183 may be any semi-conductor wafer (e.g., silicon or germanium) or other substrate as desired. It is contemplated that either or both the first substrate 185 or the second substrate 183 may be doped with an impurity to provide an n-type or p-type extrinsic semiconductor. For example, the first substrate 185 may be an n-type substrate while the second substrate 183 may be a p-type substrate. The reverse configuration is also contemplated, or both substrates may be doped the same polarity. In some instances, the first substrate 185 and/or the second substrate 183 may include an epitaxial layer.
A portion of the first substrate 185, such as a portion of the first silicon layer, may be removed, leaving a thin, flexible diaphragm 182 over a cavity or recess 181. In some cases, piezoresistors 186 may be located in or on the diaphragm 182 to measure deflection/stress of the diaphragm 182 to form a pressure sensor. During operation, at least one surface of the diaphragm 182 may be exposed to an input pressure. The diaphragm 182 may then deflect according to a magnitude of the pressure on the diaphragm 182. A deflection of the diaphragm 182 then creates changes in resistance in the piezoresistors 186. A change in resistance of the piezoresistors 186 may be reflected as a change in an output voltage signal of a resistive bridge that is formed at least partially by the piezoresistors 186. The output voltage provides a measure of the input pressure exerted on the diaphragm 182.
It is contemplated that the second substrate 183 may be flexible to allow the substrate 183 to be mounted flush against the inner surface 128 of the ocular implant 100. Alternatively, or additionally, the second substrate 183 may have a curved outer surface (facing away from the diaphragm 182) shaped to generally correspond to the curved inner surface 128 of the ocular implant 100. It is further contemplated that the materials forming the pressure sensor 180 may be selected such that the pressure sensor 180 is biocompatible.
As noted above, while the pressure sensor 180 has been described as a MEMS pressure sensor, it is contemplated that pressure sensor 180 may take other suitable forms. In one alternative example, the pressure sensor may be formed in such a way that radio waves can be used to detect changes in pressure without sensor elements incorporated into the device. Such a pressure sensor may include a flexible base substrate, a bottom inductive coil positioned on the base substrate, a layer of pressure sensitive rubber pyramids positioned over the bottom inductive coil, a top inductive coil positioned on top of the rubber pyramids, and a top substrate positioned over the top inductive coil. As a pressure is exerted on the sensor, the inductive coils move close together. Radio waves (from an applied source) reflected by the inductive coils have a lower resonance frequency when the coils are positioned closer together. Thus, the frequency of the radio waves can indicate the distance between the coils which is then correlated to the pressure exerted on the device.
The pressure sensor 180 may be further provided with an antenna or inductor 184 to allow the data from the pressure sensor 180 to be wirelessly communicated to a readout device. In some instances, the pressure sensor 180 may use radiofrequency communication protocols, such as, but not limited to cellular communication, ZigBee®, Bluetooth®, WiFi®, IrDA, dedicated short range communication (DSRC), EnOcean®, or any other suitable wireless protocols, as desired to transmit the data from the pressure sensor 180 to another device located outside the body. The data may be transmitted to any number so suitably enabled devices, including, but not limited to, cellular phones, tablet or laptop computers, desktop computers, portable handheld devices, such a personal digital assistant (PDA), or a specially designed device, such as, but not limited to a medical device. This may allow a physician, patient, or other interested party to monitor the ocular pressure without the use of a tonometer. In some instances, the pressure data may be automatically transmitted to a physician from the remote device. For example, as shown in
In the embodiment of
Ocular implant 200 may be used in conjunction with a method of treating the eye of a human patient for a disease and/or disorder (e.g., glaucoma). Some such methods may include the step of inserting a core member into a lumen defined by ocular implant 200. The core member may comprise, for example, a wire or tube. The distal end of the ocular implant may be inserted into Schlemm's canal. The ocular implant and the core member may then be advanced into Schlemm's canal until the ocular implant has reached a desired position. In some embodiments, an inlet portion of the implant may be disposed in the anterior chamber of eye while the remainder of the implant extends through the trabecular mesh into Schlemm's canal. The core member may then be withdrawn from the ocular implant, leaving the implant in place to support tissue forming Schlemm's canal. Further details of ocular implant delivery systems may be found in U.S. application Ser. No. 11/943,289, filed Nov. 20, 2007, now U.S. Pat. No. 8,512,404, the disclosure of which is incorporated herein by reference.
The flexibility and bending modulus features of the ocular implant of this invention help ensure proper orientation of the implant within Schlemm's canal.
Ocular implant 300 comprises a body 302. With reference to
An inner surface 328 of body 302 defines a channel 326. Body 302 of ocular implant 300 includes a first edge 320 and a second edge 322 that define a first opening 324. Channel 326 of ocular implant 300 fluidly communicates with first opening 324. First strut 344 of first frame 336 comprises a first edge 325A. Second strut 346 has a first edge 325B. In
A first axis 356, a second axis 358 and a third axis 360 are shown in
The ocular implant 300 may further include an intraocular pressure sensor 380 mounted to the inner surface 328 of the ocular implant 300. The pressure sensor 380 may be similar in form and function to pressure sensor 180 described above. While the pressure sensor 380 is illustrated as mounted to an inner surface 328 of the ocular implant 300 it is contemplated that the pressure sensor 380 may be mounted within one of the openings 324 or on an outer surface of the ocular implant 300, as desired. The pressure sensor 380 may continuously measure the intraocular pressure of a patient, once the ocular implant 300 has been implanted.
The pressure sensor 380 may be a Micro-Electro-Mechanical System (MEMS) pressure sensor. While the pressure sensor 380 has been described as a MEMS pressure sensor, it is contemplated that other pressure sensors may be used in place of, or in addition to, a MEMS pressure sensor. MEMS pressure sensors are often formed by anisotropically etching a recess into a back side of a silicon substrate die, leaving a thin flexible diaphragm. In operation, at least one surface of the diaphragm is exposed to an input pressure (e.g., the ocular pressure). The diaphragm deflects according to the magnitude of the input pressure, which may be detected by one or more electrical components or sense elements (e.g., piezoresistors) positioned on or embedded within the diaphragm. The change in resistance of the piezoresistors is reflected as a change in an output voltage signal from a resistive bridge formed at least in part by the piezoresistors. In some cases, the diaphragm may be made thinner with the addition of support bosses, which may help increase the sensitivity of the diaphragm over a flat plate diaphragm. Circuit elements may be connected so that sensor elements to provide some level of signal processing before providing an output signal to bond pads of the pressure sensor. The signal processing may filter, amplify, linearize, calibrate and/or otherwise process the raw sensor signal produced by the sensor elements (e.g., piezoresistors). While the sense elements have been described as piezoresistors, it is contemplated that the sense elements may be selected to provide a capacitive pressure sensor 380.
The pressure sensor 380 may be further provided with an antenna or inductor to allow the data from the pressure sensor 380 to be wirelessly communicated to a readout device. In some instances, the pressure sensor 380 may use radiofrequency communication protocols, such as, but not limited to cellular communication, ZigBee®, Bluetooth®, WiFi®, IrDA, dedicated short range communication (DSRC), EnOcean®, or any other suitable wireless protocols, as desired to transmit the data from the pressure sensor 380 to another device located outside the body. The data may be transmitted to any number so suitably enabled devices, including, but not limited to, cellular phones, tablet computers, computers, portable handheld devices, such a personal digital assistant (PDA), or a specially designed device. This may allow a physician, patient, or other interested party to monitor the ocular pressure without the use of a tonometer.
During the procedure illustrated in
Methods in accordance with this detailed description may include the step of advancing the distal end of cannula 452 through the cornea of eye 400 so that a distal portion of cannula 452 is disposed in the anterior chamber of the eye. Cannula 452 may then be used to access Schlemm's canal of the eye, for example, by piercing the wall of Schlemm's canal with the distal end of cannula 452. Distal opening 454 of cannula 452 may be placed in fluid communication with a lumen defined by Schlemm's canal. The ocular implant may be advanced out of distal opening 454 and into Schlemm's canal. Insertion of the ocular implant into Schlemm's canal may facilitate the flow of aqueous humor out of the anterior chamber of the eye.
In the embodiment of
Delivery system 500 of
Delivery system 500 of
In the embodiment of
In the embodiment of
A method in accordance with this detailed description may include the step of advancing the distal end 534 of cannula 508 through the cornea of a human eye so that distal end 534 is disposed in the anterior chamber of the eye. Cannula 508 may then be used to access Schlemm's canal of the eye, for example, by piercing the wall of Schlemm's canal with the distal end 534 of cannula 508. The beveled edge 565 may be inserted into Schlemm's canal to place at least part of distal opening 532 of cannula 508 in communication with Schlemm's canal, as discussed in more detail below. The ocular implant may be advanced out of a distal port of the cannula and into Schlemm's canal.
In the embodiment of
The cannula 508 may further include a pressure sensor 580 disposed within the trough 554. The pressure sensor 580 may be similar in form and function to pressure sensor 180 described above. While the pressure sensor 580 is illustrated as mounted within the trough 554 of the cannula, it is contemplated that the pressure sensor 580 may be mounted at other locations within or on the cannula 508. The pressure sensor 580 may provide an instantaneous pressure reading during implantation of the ocular implant 550 or shortly thereafter. In some instances, the pressure reading obtained from the pressure sensor 580 on the cannula 508 can be compared to a pressure reading obtained from a pressure sensor mounted on the ocular implant 550, if so provided.
The pressure sensor 580 may be a Micro-Electro-Mechanical System (MEMS) pressure sensor. While the pressure sensor 580 has been described as a MEMS pressure sensor, it is contemplated that other pressure sensors may be used in place of, or in addition to, a MEMS pressure sensor. Further, while only a single pressure sensor 580 has been illustrated, the cannula 508 may include more than one pressure sensor 580, as desired. MEMS pressure sensors are often formed by anisotropically etching a recess into a back side of a silicon substrate die, leaving a thin flexible diaphragm. In operation, at least one surface of the diaphragm is exposed to an input pressure (e.g., the ocular pressure). The diaphragm deflects according to the magnitude of the input pressure, which may be detected by one or more electrical components or sense elements (e.g., piezoresistors) positioned on or embedded within the diaphragm. The change in resistance of the piezoresistors is reflected as a change in an output voltage signal from a resistive bridge formed at least in part by the piezoresistors. In some cases, the diaphragm may be made thinner with the addition of support bosses, which may help increase the sensitivity of the diaphragm over a flat plate diaphragm. Circuit elements may be connected so that sensor elements to provide some level of signal processing before providing an output signal to bond pads of the pressure sensor. The signal processing may filter, amplify, linearize, calibrate and/or otherwise process the raw sensor signal produced by the sensor elements (e.g., piezoresistors). While the sense elements have been described as piezoresistors, it is contemplated that the sense elements may be selected to provide a capacitive pressure sensor 580.
The pressure sensor 580 may be further provided with an antenna or inductor to allow the data from the pressure sensor 580 to be wirelessly communicated to a readout device. In some instances, the pressure sensor 580 may use radiofrequency communication protocols, such as, but not limited to cellular communication, ZigBee®, Bluetooth®, IrDA, dedicated short range communication (DSRC), EnOcean®, or any other suitable wireless protocols, as desired to transmit the data from the pressure sensor 580 to another device located outside the body. The data may be transmitted to any number so suitably enabled devices, including, but not limited to, cellular phones, tablet computers, computers, portable handheld devices, such a personal digital assistant (PDA), or a specially designed device. This may allow a physician, patient, or other interested party to monitor the ocular pressure without the use of a tonometer.
For purposes of illustration, a hypothetical window W is cut through the wall of cannula 508 in
As shown in
In some useful embodiments, the delivery tool may be colored to provide visual differentiation from the implant. After the disengaging from the ocular implant, cannula 508 and delivery tool 552 can be withdrawn from Schlemm's canal SC leaving the ocular implant 550 in the fully deployed position shown in
In some instances, it may be desirable to deliver an ocular implant to Schlemm's canal in conjunction with another corrective surgery, such as, but not limited to, cataract surgery. When the ocular implant is placed during another surgical procedure, it may be desirable to insert the ocular implant through the same incision used for the other procedure.
Delivery system 600 of
Delivery system 600 of
In the embodiment of
In some instances, it may be desirable to place the ocular implant 650 during another ocular procedure, such as, but not limited to cataract surgery. It is contemplated that the optimal position for an incision for cataract surgery may not be the same as the optimal position of an incision for solely placing an ocular implant, such as implant 650, into Schlemm's canal. With previous ocular implant delivery system designs, in order to allow for substantially tangential entry of the cannula into Schlemm's canal two separate incisions may be required when the implant is placed in combination with another ocular procedure. The curved configuration of both the distal portion 644 may be configured to allow for substantially tangential entry of the cannula 608 into Schlemm's canal. It is further contemplated that the curved configuration of the intermediate portion 645 may allow the cannula 608 to be advanced through typical incisions associated with and/or optimized for cataract surgery, such as, but not limited to, a sclerocorneal tunnel incision, while still allowing for substantially tangential entry of the cannula 608 into Schlemm's canal. This may allow for two or more ocular procedures to be performed using a single incision. It is further contemplated that performing multiple procedures through a single incision may reduce patient discomfort and recovery time.
In the embodiment of
Delivery system 600 includes a mechanism 617 that controls the movement of delivery tool subassembly 670. Mechanism 617 includes a number of components that are located inside housing 602, including tracking wheel 606, an idler gear 622, and the rotating rack gear 620. In the embodiment of
In the embodiment of
In the embodiment of
In some embodiments, delivery tool 652 is formed from shape memory material (such as, e.g., nitinol), and at least a portion of delivery tool 652 assumes a curved at-rest shape when no external forces are acting on it. Delivery tool 652 can be urged to assume a straightened shape, for example, by inserting delivery tool 652 through a straight portion of the passageway defined by cannula 608. When the delivery tool 652 is confined, such as within cannula 608, the interlocking portion can engage the complementary interlocking portion to join the delivery tool and ocular implant together, and allow the delivery tool and ocular implant to move together through the cannula 608, as described in more detail below.
A distal opening surface 642 surrounds a distal opening 632 extending through the distal end 634 and through a side wall of cannula 608. A beveled edge 665 is disposed at the distal end of distal opening surface 642, extending from the distal end 634 to a proximal extent 667 of beveled edge 665. Tubular member 698 defines distal opening 632, a proximal opening 636, and a passageway 638 extending between proximal opening 636 and distal opening 632.
Proximal portion 640 of cannula 608 is substantially straight while intermediate portion 645 and distal portion 644 of cannula 608 may be curved. In the embodiment of
where Larc is the length of the arc, θ is the angle measure of the arc (in degrees), and r is the radius of the circle. In some instances, the angle measure of intermediate portion 645 may be in the range of 10° to 25°, although other angles are possible. Distal portion 644 may define a curve having a second radius R2 and defining a second radius of curvature. The length of distal portion 644 along central axis 696 may be determined by the measure of the arc (in degrees) and the radius of the curve using Equation 1 above. In some instances, the angle measure of distal portion 644 may be in the range of 90° to 110°, although other angles are possible. It is contemplated that the first radius R1 may be larger than the second radius R2 such that the distal portion 644 has a higher curvature than the intermediate portion 645. This configuration may advance the ocular implant at the correct trajectory relative to Schlemm's canal or other anatomy in the eye into which the ocular implant is to be implanted. For example, the configuration may allow the cannula 608 to be advanced through an incision generally along a major axis of the visible eye and allowing for substantially tangential entry of cannula 608 into Schlemm's canal. It is contemplated that first radius R1 and second radius R2 may be selected to facilitate delivery of implant 650 to other anatomical locations.
A method in accordance with this detailed description may include the step of advancing the distal end 634 of cannula 608 through the cornea of a human eye so that distal end 634 is disposed in the anterior chamber of the eye. Cannula 608 may then be used to access Schlemm's canal of the eye, for example, by piercing the wall of Schlemm's canal with the distal end 634 of cannula 608. The beveled edge 665 may be inserted into Schlemm's canal to place at least part of distal opening 632 of cannula 608 in communication with Schlemm's canal. For example, cannula 608 may be advanced until the distal tip 634 and beveled edge 665 of cannula 608 have been inserted into Schlemm's canal up to the proximal extent 667 of beveled edge 665. With the passageway of the cannula 608 placed in fluid communication with the lumen of Schlemm's canal, the ocular implant may be advanced out of a distal port of the cannula 608 and into Schlemm's canal.
In the embodiment of
Referring briefly to
Once cannula 608 has been positioned in the desired location, ocular implant 650 may be advanced distally while cannula 608 is held stationary. Elongate opening 632 may provide direct visualization of ocular implant 650 as it is advanced into Schlemm's canal. A configuration allowing direct visualization of the ocular implant has a number of clinical advantages. During a medical procedure, it is often difficult to monitor the progress of the implant by viewing the implant through the trabecular meshwork. For example, blood reflux may push blood into Schlemm's canal obstructing a physician's view the portion of the implant that has entered Schlemm's canal. Ocular implant 650 tracks along trough 654 as it is advanced distally along cannula 608. The trough opening allows the physician to monitor the progress of the implant by viewing the implant structures as they advance through the trough prior to entering Schlemm's canal. The trough opening also allows the physician to identify the position of the proximal end of the ocular implant with respect to the incision made by the cannula to access Schlemm's canal.
Delivery tool 652 may advance ocular implant 650 distally until delivery tool surface 661 and part of the reduced diameter portion 663 have now passed into opening 632, thereby permitting the delivery tool curved portion to move toward its curved at-rest shape so that the delivery tool engagement surface 660 disengages and moves away from its complementary engagement surface 662 on the ocular implant 650. After the disengaging from the ocular implant, cannula 608 and delivery tool 652 can be withdrawn from Schlemm's canal leaving the ocular implant 650 in the fully deployed position. After delivery of ocular implant 650 is complete, the delivery tool 652 and the cannula 608 may be removed from the eye, leaving at least a distal portion of the ocular implant 650 in Schlemm's canal. An inlet portion of ocular implant 650 may be positioned in the anterior chamber of the eye and the remainder of ocular implant 650 in Schlemm's canal. The presence of ocular implant 650 in Schlemm's canal may facilitate the flow of aqueous humor out of the anterior chamber. This flow may include axial flow along Schlemm's canal, flow from the anterior chamber into Schlemm's canal, and flow leaving Schlemm's canal via outlets communicating with Schlemm's canal. When in place within the eye, ocular implant 650 will support the trabecular meshwork and Schlemm's canal tissue and will provide for improved communication between the anterior chamber and Schlemm's canal (via the trabecular meshwork) and between pockets or compartments along Schlemm's canal.
The cannula 608 may further include a pressure sensor 690 disposed within the trough 654. The pressure sensor 690 may be similar in form and function to pressure sensor 180 described above. While the pressure sensor 690 is illustrated as mounted within the trough 654 of the cannula, it is contemplated that the pressure sensor 690 may be mounted at other locations within or on the cannula 608. The pressure sensor 690 may provide an instantaneous pressure reading during implantation of the ocular implant 650 or shortly thereafter. In some instances, the pressure reading obtained from the pressure sensor 690 on the cannula 608 can be compared to a pressure reading obtained from a pressure sensor mounted on the ocular implant 650, if so provided.
The pressure sensor 690 may be a Micro-Electro-Mechanical System (MEMS) pressure sensor. While the pressure sensor 690 has been described as a MEMS pressure sensor, it is contemplated that other pressure sensors may be used in place of, or in addition to, a MEMS pressure sensor. Further, while only a single pressure sensor 690 has been illustrated, the cannula 608 may include more than one pressure sensor 690, as desired. MEMS pressure sensors are often formed by anisotropically etching a recess into a back side of a silicon substrate die, leaving a thin flexible diaphragm. In operation, at least one surface of the diaphragm is exposed to an input pressure (e.g., the ocular pressure). The diaphragm deflects according to the magnitude of the input pressure, which may be detected by one or more electrical components or sense elements (e.g., piezoresistors) positioned on or embedded within the diaphragm. The change in resistance of the piezoresistors is reflected as a change in an output voltage signal from a resistive bridge formed at least in part by the piezoresistors. In some cases, the diaphragm may be made thinner with the addition of support bosses, which may help increase the sensitivity of the diaphragm over a flat plate diaphragm. Circuit elements may be connected so that sensor elements to provide some level of signal processing before providing an output signal to bond pads of the pressure sensor. The signal processing may filter, amplify, linearize, calibrate and/or otherwise process the raw sensor signal produced by the sensor elements (e.g., piezoresistors). While the sense elements have been described as piezoresistors, it is contemplated that the sense elements may be selected to provide a capacitive pressure sensor 690.
The pressure sensor 690 may be further provided with an antenna or inductor to allow the data from the pressure sensor 690 to be wirelessly communicated to a readout device. In some instances, the pressure sensor 690 may use radiofrequency communication protocols, such as, but not limited to cellular communication, ZigBee®, Bluetooth®, WiFi®, IrDA, dedicated short range communication (DSRC), EnOcean®, or any other suitable wireless protocols, as desired to transmit the data from the pressure sensor 690 to another device located outside the body. The data may be transmitted to any number so suitably enabled devices, including, but not limited to, cellular phones, tablet computers, computers, portable handheld devices, such a personal digital assistant (PDA), or a specially designed device. This may allow a physician, patient, or other interested party to monitor the ocular pressure without the use of a tonometer.
An ocular implant, such as any of those described above, may lower the intraocular pressure from its initial, or pretreatment, pressure to a second pressure. The second pressure may be lower than the initial or first pressure. For example, the second pressure may be in the range of 65% to 95% of the initial pressure or in the range of 75% to 85% of the initial pressure. The second intraocular pressure may be within the range of 20 to 30 mm Hg or 23 to 28 mm Hg. These ranges are just examples. The ocular implant may lower the intraocular pressure from the initial pressure to a value above 30 mm Hg or below 20 mm Hg.
In some instances, the intraocular pressure of a patient may need to be lowered beyond the capabilities of an ocular implant, such as any of those described above. In such instances, it may be desirable to administer a therapeutic drug in combination with deploying an ocular implant, such as implant 100, within a portion of Schlemm's canal. The therapeutic agent may be any agent that may be used to reduce intraocular pressure. Some categories of drug therapy for glaucoma may include but are not limited to: (1) Miotics (e.g., pilocarpine, carbachol, and ace-tylcholinesterase inhibitors), (2) Sympathomimetics (e.g., epinephrine and dipivalylepinephxine), (3) Beta-blockers (e.g., betaxolol, levobunolol and timolol), (4) Carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide and ethoxzolamide), (5) Prostaglandins (e.g., metabolite derivatives of arachidonic acid), and (6) Rho-kinase (ROCK) inhibitors. The Rho family consists of three small guanosine triphosphate (GTP)-binding proteins (RhoA, RhoB, RhoC), which regulate aspects of cell shape, motility, proliferation, and apoptosis throughout the body. ROCK inhibitors may work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This may result in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. In some instances, ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. It is contemplated that other therapeutic agents, such as those described with respect to
The therapeutic agent may be administered to a patient before or after the implantation of the ocular implant, as desired. When administered after the implantation of an ocular implant, the therapeutic agent may further lower the intraocular pressure from the second pressure (which is lower than the initial pressure) to a third pressure lower than both the initial pressure and the second pressure. For example, the second pressure may be in the range of 65% to 95% of the second pressure (e.g., the lower pressure resulting from the delivery of the ocular implant) or in the range of 75% to 85% of the second pressure. The second intraocular pressure may be within the range of 13 to 23 mm Hg or 15 to 20 mm Hg. These ranges are just examples. The ocular implant may lower the intraocular pressure from the initial pressure to a value above 23 mm Hg or below 15 mm Hg.
Components of ocular device may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, utylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.
As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.
In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (° C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
This application is related to U.S. Pat. No. 7,740,604, issued Jun. 22, 2010, and also U.S. Application No. 62/110,293, filed Jan. 30, 2015, the disclosures of which are incorporated by reference as if fully set forth herein.
It is to be understood that even though numerous characteristics of various embodiments have been set forth in the foregoing description, together with details of the structure and function of various embodiments, this detailed description is illustrative only, and changes may be made in detail, especially in matters of structure and arrangements of parts illustrated by the various embodiments to the full extent indicated by the broad general meaning of the terms in which the appended claims are expressed.
This application claims the benefit under 35 U.S.C. § 119 of U.S. Patent Appl. No. 62/267,794 filed Dec. 15, 2015, the disclosure of which is incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/066957 | 12/15/2016 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/106517 | 6/22/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 703296 | Arnold | Jun 1902 | A |
| 1601709 | Windom | Oct 1926 | A |
| 2716983 | George et al. | Sep 1955 | A |
| 3071135 | Baldwin et al. | Jan 1963 | A |
| 3788327 | Donowitz et al. | Jan 1974 | A |
| 3811442 | Maroth | May 1974 | A |
| 3858577 | Bass et al. | Jan 1975 | A |
| 3884236 | Krasnov | May 1975 | A |
| 3948271 | Akiyama | Apr 1976 | A |
| 3982541 | L'Esperance | Sep 1976 | A |
| 4037604 | Newkirk | Jul 1977 | A |
| 4134405 | Smit | Jan 1979 | A |
| 4273109 | Enderby | Jun 1981 | A |
| 4391275 | Fankhauser et al. | Jul 1983 | A |
| 4428746 | Mendez | Jan 1984 | A |
| 4457757 | Molteno | Jul 1984 | A |
| 4461294 | Baron | Jul 1984 | A |
| 4470407 | Hussein | Sep 1984 | A |
| 4497319 | Sekine et al. | Feb 1985 | A |
| 4501274 | Skjaerpe | Feb 1985 | A |
| 4517973 | Sunago et al. | May 1985 | A |
| 4538608 | L'Esperance | Sep 1985 | A |
| 4548205 | Armeniades et al. | Oct 1985 | A |
| 4551129 | Coleman et al. | Nov 1985 | A |
| 4558698 | O'Dell | Dec 1985 | A |
| 4559942 | Eisenberg | Dec 1985 | A |
| 4566438 | Liese et al. | Jan 1986 | A |
| 4580559 | L'Esperance | Apr 1986 | A |
| 4583539 | Karlin et al. | Apr 1986 | A |
| 4601713 | Fuquo | Jul 1986 | A |
| 4604087 | Joseph | Aug 1986 | A |
| 4633866 | Peyman et al. | Jan 1987 | A |
| 4658816 | Ector | Apr 1987 | A |
| 4660546 | Herrick et al. | Apr 1987 | A |
| 4671273 | Lindsey | Jun 1987 | A |
| 4689040 | Thompson | Aug 1987 | A |
| 4699140 | Holmes et al. | Oct 1987 | A |
| 4706669 | Schlegel | Nov 1987 | A |
| 4722350 | Armeniades et al. | Feb 1988 | A |
| 4722724 | Schocket | Feb 1988 | A |
| 4729373 | Peyman | Mar 1988 | A |
| 4733665 | Palmaz | Mar 1988 | A |
| 4750901 | Molteno | Jun 1988 | A |
| 4770654 | Rogers et al. | Sep 1988 | A |
| 4791927 | Menger | Dec 1988 | A |
| 4826478 | Schocket | May 1989 | A |
| 4846172 | Berlin | Jul 1989 | A |
| 4861341 | Woodburn | Aug 1989 | A |
| 4876250 | Clark | Oct 1989 | A |
| 4880000 | Holmes et al. | Nov 1989 | A |
| 4886488 | White | Dec 1989 | A |
| 4919130 | Stoy et al. | Apr 1990 | A |
| 4925299 | Meisberger et al. | May 1990 | A |
| 4934363 | Smith et al. | Jun 1990 | A |
| 4934809 | Volk | Jun 1990 | A |
| 4936825 | Ungerleider | Jun 1990 | A |
| 4946436 | Smith | Aug 1990 | A |
| 4968296 | Ritch et al. | Nov 1990 | A |
| 4994060 | Rink et al. | Feb 1991 | A |
| 5034010 | Kittrell et al. | Jul 1991 | A |
| 5092837 | Ritch et al. | Mar 1992 | A |
| 5123902 | Muller et al. | Jun 1992 | A |
| 5127901 | Odrich | Jul 1992 | A |
| 5129895 | Vassiliadis et al. | Jul 1992 | A |
| 5178604 | Baerveldt et al. | Jan 1993 | A |
| 5180362 | Worst | Jan 1993 | A |
| 5190552 | Kelman | Mar 1993 | A |
| 5213569 | Davis | May 1993 | A |
| 5238004 | Sahatjian et al. | Aug 1993 | A |
| 5246452 | Sinnott | Sep 1993 | A |
| 5254112 | Sinofsky et al. | Oct 1993 | A |
| 5273056 | McLaughlin et al. | Dec 1993 | A |
| 5290267 | Zimmermann | Mar 1994 | A |
| 5300020 | L'Esperance | Apr 1994 | A |
| 5359685 | Waynant et al. | Oct 1994 | A |
| 5360399 | Stegmann | Nov 1994 | A |
| 5371078 | Clark et al. | Dec 1994 | A |
| 5372577 | Ungerleider | Dec 1994 | A |
| 5445637 | Bretton | Aug 1995 | A |
| 5454796 | Krupin | Oct 1995 | A |
| 5458615 | Klemm et al. | Oct 1995 | A |
| 5501274 | Nguyen et al. | Mar 1996 | A |
| 5536259 | Utterberg | Jul 1996 | A |
| 5575780 | Saito | Nov 1996 | A |
| 5591223 | Lock et al. | Jan 1997 | A |
| 5607966 | Hellberg et al. | Mar 1997 | A |
| 5613972 | Lee et al. | Mar 1997 | A |
| 5626558 | Suson | May 1997 | A |
| 5643250 | O'Donnell | Jul 1997 | A |
| 5653753 | Brady et al. | Aug 1997 | A |
| 5657760 | Ying et al. | Aug 1997 | A |
| 5676669 | Colvard | Oct 1997 | A |
| 5704907 | Nordquist et al. | Jan 1998 | A |
| 5713844 | Peyman | Feb 1998 | A |
| 5722970 | Colvard et al. | Mar 1998 | A |
| 5736491 | Patel et al. | Apr 1998 | A |
| 5738676 | Hammer et al. | Apr 1998 | A |
| 5738677 | Colvard et al. | Apr 1998 | A |
| 5785658 | Benaron et al. | Jul 1998 | A |
| 5792099 | DeCamp et al. | Aug 1998 | A |
| 5792103 | Schwartz et al. | Aug 1998 | A |
| 5807302 | Wandel | Sep 1998 | A |
| 5811453 | Yanni et al. | Sep 1998 | A |
| 5865831 | Cozean et al. | Feb 1999 | A |
| 5868697 | Richter et al. | Feb 1999 | A |
| 5879319 | Pynson et al. | Mar 1999 | A |
| 5885279 | Bretton | Mar 1999 | A |
| 5893837 | Eagles et al. | Apr 1999 | A |
| 5895831 | Brasier et al. | Apr 1999 | A |
| 5919171 | Kira et al. | Jul 1999 | A |
| 5948427 | Yamamoto et al. | Sep 1999 | A |
| 5968058 | Richter et al. | Oct 1999 | A |
| 5990099 | Clark | Nov 1999 | A |
| 5993438 | Juhasz et al. | Nov 1999 | A |
| 5997531 | Loeb et al. | Dec 1999 | A |
| 6002480 | Izatt et al. | Dec 1999 | A |
| 6007511 | Prywes | Dec 1999 | A |
| 6050970 | Baerveldt | Apr 2000 | A |
| 6083193 | Kadziauskas et al. | Jul 2000 | A |
| 6099521 | Shadduck | Aug 2000 | A |
| 6102045 | Nordquist et al. | Aug 2000 | A |
| 6142990 | Burk | Nov 2000 | A |
| 6146375 | Juhasz et al. | Nov 2000 | A |
| 6177544 | Kanai et al. | Jan 2001 | B1 |
| 6186974 | Allan et al. | Feb 2001 | B1 |
| 6217584 | Nun | Apr 2001 | B1 |
| 6221078 | Bylsma | Apr 2001 | B1 |
| 6238409 | Hojeibane | May 2001 | B1 |
| 6241721 | Cozean et al. | Jun 2001 | B1 |
| D444874 | Haffner et al. | Jul 2001 | S |
| 6297228 | Clark | Oct 2001 | B1 |
| 6319274 | Shadduck | Nov 2001 | B1 |
| 6328747 | Nun | Dec 2001 | B1 |
| 6375642 | Grieshaber et al. | Apr 2002 | B1 |
| 6398809 | Hoffmann et al. | Jun 2002 | B1 |
| 6409752 | Boatman et al. | Jun 2002 | B1 |
| 6450984 | Lynch et al. | Sep 2002 | B1 |
| 6464724 | Lynch et al. | Oct 2002 | B1 |
| 6471666 | Odrich | Oct 2002 | B1 |
| 6494857 | Neuhann | Dec 2002 | B1 |
| 6508779 | Suson | Jan 2003 | B1 |
| 6508803 | Horikawa et al. | Jan 2003 | B1 |
| 6517523 | Kaneko et al. | Feb 2003 | B1 |
| 6524275 | Lynch et al. | Feb 2003 | B1 |
| 6533764 | Haffner et al. | Mar 2003 | B1 |
| 6533768 | Hill | Mar 2003 | B1 |
| 6544208 | Ethier et al. | Apr 2003 | B2 |
| 6544249 | Yu et al. | Apr 2003 | B1 |
| 6551289 | Higuchi et al. | Apr 2003 | B1 |
| 6626858 | Lynch et al. | Sep 2003 | B2 |
| 6638239 | Bergheim et al. | Oct 2003 | B1 |
| 6666841 | Gharib et al. | Dec 2003 | B2 |
| 6699210 | Williams et al. | Mar 2004 | B2 |
| 6699211 | Savage | Mar 2004 | B2 |
| 6702790 | Ross | Mar 2004 | B1 |
| 6726676 | Stegmann et al. | Apr 2004 | B2 |
| D490152 | Myall et al. | May 2004 | S |
| 6730056 | Ghaem et al. | May 2004 | B1 |
| 6736791 | Tu et al. | May 2004 | B1 |
| 6780164 | Bergheim et al. | Aug 2004 | B2 |
| 6783544 | Lynch et al. | Aug 2004 | B2 |
| 6827699 | Lynch et al. | Dec 2004 | B2 |
| 6827700 | Lynch et al. | Dec 2004 | B2 |
| 6881198 | Brown | Apr 2005 | B2 |
| 6899717 | Weber et al. | May 2005 | B2 |
| 6939298 | Brown et al. | Sep 2005 | B2 |
| 6939299 | Petersen | Sep 2005 | B1 |
| 6955656 | Bergheim et al. | Oct 2005 | B2 |
| 6962573 | Wilcox | Nov 2005 | B1 |
| 6981958 | Gharib et al. | Jan 2006 | B1 |
| 6989007 | Shadduck | Jan 2006 | B2 |
| 7018376 | Webb et al. | Mar 2006 | B2 |
| 7094225 | Tu et al. | Aug 2006 | B2 |
| 7125119 | Farberov | Oct 2006 | B2 |
| 7133137 | Shimmick | Nov 2006 | B2 |
| 7135009 | Tu et al. | Nov 2006 | B2 |
| 7147650 | Lee | Dec 2006 | B2 |
| 7163543 | Smedley et al. | Jan 2007 | B2 |
| 7186232 | Smedley et al. | Mar 2007 | B1 |
| 7192412 | Zhou et al. | Mar 2007 | B1 |
| 7207965 | Simon | Apr 2007 | B2 |
| 7207980 | Christian et al. | Apr 2007 | B2 |
| 7220238 | Lynch et al. | May 2007 | B2 |
| 7273475 | Tu et al. | Sep 2007 | B2 |
| 7297130 | Bergheim et al. | Nov 2007 | B2 |
| 7331984 | Tu et al. | Feb 2008 | B2 |
| 7488303 | Haffner et al. | Feb 2009 | B1 |
| 7699882 | Stamper et al. | Apr 2010 | B2 |
| 7740604 | Schieber et al. | Jun 2010 | B2 |
| 7931596 | Rachlin et al. | Apr 2011 | B2 |
| 7967772 | McKenzie et al. | Jun 2011 | B2 |
| 8012115 | Karageozian | Sep 2011 | B2 |
| 8123729 | Yamamoto et al. | Feb 2012 | B2 |
| 8172899 | Silvestrini et al. | May 2012 | B2 |
| 8267882 | Euteneuer et al. | Sep 2012 | B2 |
| 8282592 | Schieber et al. | Oct 2012 | B2 |
| 8308701 | Horvath et al. | Nov 2012 | B2 |
| 8337509 | Schieber et al. | Dec 2012 | B2 |
| 8372026 | Schieber et al. | Feb 2013 | B2 |
| 8414518 | Schieber et al. | Apr 2013 | B2 |
| 8425449 | Wardle et al. | Apr 2013 | B2 |
| 8475374 | Irazoqui et al. | Jul 2013 | B2 |
| 8512404 | Frion et al. | Aug 2013 | B2 |
| 8529494 | Euteneuer et al. | Sep 2013 | B2 |
| 8540659 | Berlin | Sep 2013 | B2 |
| 8551166 | Schieber et al. | Oct 2013 | B2 |
| 8629161 | Mizuno et al. | Jan 2014 | B2 |
| 8636647 | Silvestrini et al. | Jan 2014 | B2 |
| 8647659 | Robinson et al. | Feb 2014 | B2 |
| 8657776 | Wardle et al. | Feb 2014 | B2 |
| 8663150 | Wardle et al. | Mar 2014 | B2 |
| 8663303 | Horvath et al. | Mar 2014 | B2 |
| 8734377 | Schieber et al. | May 2014 | B2 |
| 8808222 | Schieber et al. | Aug 2014 | B2 |
| 8939906 | Huang et al. | Jan 2015 | B2 |
| 8939948 | De Juan, Jr. et al. | Jan 2015 | B2 |
| 8945038 | Yablonski | Feb 2015 | B2 |
| 8951221 | Stegmann et al. | Feb 2015 | B2 |
| 8961447 | Schieber et al. | Feb 2015 | B2 |
| 8974511 | Horvath et al. | Mar 2015 | B2 |
| 9039650 | Schieber et al. | May 2015 | B2 |
| 9050169 | Schieber et al. | Jun 2015 | B2 |
| 9066750 | Wardle et al. | Jun 2015 | B2 |
| 9066783 | Euteneuer et al. | Jun 2015 | B2 |
| 9155655 | Wardle et al. | Oct 2015 | B2 |
| 9211213 | Wardle et al. | Dec 2015 | B2 |
| 9226852 | Schieber et al. | Jan 2016 | B2 |
| 9301875 | Tu et al. | Apr 2016 | B2 |
| 9351874 | Schieber et al. | May 2016 | B2 |
| 9358156 | Wardle et al. | Jun 2016 | B2 |
| 9402767 | Schieber et al. | Aug 2016 | B2 |
| 9510973 | Wardle | Dec 2016 | B2 |
| 9579234 | Wardle et al. | Feb 2017 | B2 |
| 9603741 | Berlin | Mar 2017 | B2 |
| 9610196 | Schieber et al. | Apr 2017 | B2 |
| 9636254 | Yu et al. | May 2017 | B2 |
| 9642746 | Berlin | May 2017 | B2 |
| 9693899 | Wardle et al. | Jul 2017 | B2 |
| 9693901 | Horvath et al. | Jul 2017 | B2 |
| 9693902 | Euteneuer et al. | Jul 2017 | B2 |
| 9730638 | Haffner et al. | Aug 2017 | B2 |
| 9757276 | Penhasi | Sep 2017 | B2 |
| 9775729 | McClain et al. | Oct 2017 | B2 |
| 9782293 | Doci | Oct 2017 | B2 |
| 9788999 | Schaller | Oct 2017 | B2 |
| 9795503 | Perez Grossmann | Oct 2017 | B2 |
| 9808373 | Horvath et al. | Nov 2017 | B2 |
| 9820883 | Berlin | Nov 2017 | B2 |
| 9833357 | Berlin | Dec 2017 | B2 |
| 9931243 | Wardle et al. | Apr 2018 | B2 |
| 10390993 | Berlin | Aug 2019 | B1 |
| 20010002438 | Sepetka et al. | May 2001 | A1 |
| 20020003546 | Mochimaru et al. | Jan 2002 | A1 |
| 20020013546 | Grieshaber et al. | Jan 2002 | A1 |
| 20020013572 | Berlin | Jan 2002 | A1 |
| 20020052653 | Durgin | May 2002 | A1 |
| 20020072673 | Yamamoto et al. | Jun 2002 | A1 |
| 20020082591 | Haefliger | Jun 2002 | A1 |
| 20020133168 | Smedley et al. | Sep 2002 | A1 |
| 20020143284 | Tu et al. | Oct 2002 | A1 |
| 20020165504 | Sharp et al. | Nov 2002 | A1 |
| 20020165522 | Holmen | Nov 2002 | A1 |
| 20020193805 | Ott et al. | Dec 2002 | A1 |
| 20030004457 | Andersson | Jan 2003 | A1 |
| 20030014092 | Neuhann | Jan 2003 | A1 |
| 20030040754 | Mitchell et al. | Feb 2003 | A1 |
| 20030055372 | Lynch et al. | Mar 2003 | A1 |
| 20030060748 | Baikoff | Mar 2003 | A1 |
| 20030060752 | Bergheim et al. | Mar 2003 | A1 |
| 20030060784 | Hilgers et al. | Mar 2003 | A1 |
| 20030093084 | Nissan et al. | May 2003 | A1 |
| 20030097151 | Smedley et al. | May 2003 | A1 |
| 20030105456 | Lin | Jun 2003 | A1 |
| 20030125351 | Azuma et al. | Jul 2003 | A1 |
| 20030175324 | Robinson et al. | Sep 2003 | A1 |
| 20030181848 | Bergheim et al. | Sep 2003 | A1 |
| 20030187384 | Bergheim et al. | Oct 2003 | A1 |
| 20030212387 | Kurtz et al. | Nov 2003 | A1 |
| 20030229303 | Haffner et al. | Dec 2003 | A1 |
| 20030236483 | Ren | Dec 2003 | A1 |
| 20030236484 | Lynch et al. | Dec 2003 | A1 |
| 20040024345 | Gharib et al. | Feb 2004 | A1 |
| 20040024453 | Castillejos | Feb 2004 | A1 |
| 20040030302 | Kamata et al. | Feb 2004 | A1 |
| 20040070761 | Horvath et al. | Apr 2004 | A1 |
| 20040082939 | Berlin | Apr 2004 | A1 |
| 20040088048 | Richter et al. | May 2004 | A1 |
| 20040092856 | Dahan | May 2004 | A1 |
| 20040098124 | Freeman et al. | May 2004 | A1 |
| 20040102729 | Haffner et al. | May 2004 | A1 |
| 20040106975 | Solovay et al. | Jun 2004 | A1 |
| 20040111050 | Smedley et al. | Jun 2004 | A1 |
| 20040116909 | Neuberger et al. | Jun 2004 | A1 |
| 20040122380 | Utterberg | Jun 2004 | A1 |
| 20040127843 | Tu et al. | Jul 2004 | A1 |
| 20040147870 | Burns et al. | Jul 2004 | A1 |
| 20040193095 | Shadduck | Sep 2004 | A1 |
| 20040193262 | Shadduck | Sep 2004 | A1 |
| 20040199149 | Myers et al. | Oct 2004 | A1 |
| 20040199171 | Akahoshi | Oct 2004 | A1 |
| 20040210181 | Vass et al. | Oct 2004 | A1 |
| 20040210185 | Tu et al. | Oct 2004 | A1 |
| 20040216749 | Tu | Nov 2004 | A1 |
| 20040225357 | Worst et al. | Nov 2004 | A1 |
| 20040228013 | Goldstein et al. | Nov 2004 | A1 |
| 20040249333 | Bergheim et al. | Dec 2004 | A1 |
| 20040254517 | Quiroz-Mercado et al. | Dec 2004 | A1 |
| 20040254519 | Tu et al. | Dec 2004 | A1 |
| 20040254520 | Porteous et al. | Dec 2004 | A1 |
| 20040260228 | Lynch et al. | Dec 2004 | A1 |
| 20050041200 | Rich | Feb 2005 | A1 |
| 20050043722 | Lin | Feb 2005 | A1 |
| 20050049578 | Tu et al. | Mar 2005 | A1 |
| 20050090806 | Lynch et al. | Apr 2005 | A1 |
| 20050090807 | Lynch et al. | Apr 2005 | A1 |
| 20050101967 | Weber et al. | May 2005 | A1 |
| 20050107734 | Coroneo | May 2005 | A1 |
| 20050119601 | Lynch et al. | Jun 2005 | A9 |
| 20050119636 | Haffner et al. | Jun 2005 | A1 |
| 20050125003 | Pinchuk et al. | Jun 2005 | A1 |
| 20050131514 | Hijlkema et al. | Jun 2005 | A1 |
| 20050149114 | Cartledge et al. | Jul 2005 | A1 |
| 20050154443 | Linder et al. | Jul 2005 | A1 |
| 20050165385 | Simon | Jul 2005 | A1 |
| 20050192527 | Gharib et al. | Sep 2005 | A1 |
| 20050197667 | Chan et al. | Sep 2005 | A1 |
| 20050203542 | Weber et al. | Sep 2005 | A1 |
| 20050209549 | Bergheim et al. | Sep 2005 | A1 |
| 20050209550 | Bergheim et al. | Sep 2005 | A1 |
| 20050240168 | Neuberger et al. | Oct 2005 | A1 |
| 20050244464 | Hughes | Nov 2005 | A1 |
| 20050245916 | Connor | Nov 2005 | A1 |
| 20050250788 | Tu et al. | Nov 2005 | A1 |
| 20050260186 | Bookbinder et al. | Nov 2005 | A1 |
| 20050266047 | Tu et al. | Dec 2005 | A1 |
| 20050271704 | Tu et al. | Dec 2005 | A1 |
| 20050273033 | Grahn et al. | Dec 2005 | A1 |
| 20050277864 | Haffner et al. | Dec 2005 | A1 |
| 20050279369 | Lin | Dec 2005 | A1 |
| 20050288619 | Gharib et al. | Dec 2005 | A1 |
| 20050288745 | Andersen et al. | Dec 2005 | A1 |
| 20060020247 | Kagan et al. | Jan 2006 | A1 |
| 20060021623 | Miller et al. | Feb 2006 | A1 |
| 20060032507 | Tu | Feb 2006 | A1 |
| 20060052879 | Kolb | Mar 2006 | A1 |
| 20060069340 | Simon | Mar 2006 | A1 |
| 20060074375 | Bergheim et al. | Apr 2006 | A1 |
| 20060079828 | Brown | Apr 2006 | A1 |
| 20060084907 | Bergheim et al. | Apr 2006 | A1 |
| 20060084954 | Zadoyan et al. | Apr 2006 | A1 |
| 20060106370 | Baerveldt et al. | May 2006 | A1 |
| 20060110428 | deJuan et al. | May 2006 | A1 |
| 20060116626 | Smedley et al. | Jun 2006 | A1 |
| 20060129141 | Lin | Jun 2006 | A1 |
| 20060149194 | Conston et al. | Jul 2006 | A1 |
| 20060154981 | Klimko et al. | Jul 2006 | A1 |
| 20060155238 | Shields | Jul 2006 | A1 |
| 20060155265 | Juhasz et al. | Jul 2006 | A1 |
| 20060155300 | Stamper et al. | Jul 2006 | A1 |
| 20060167421 | Quinn | Jul 2006 | A1 |
| 20060167466 | Dusek | Jul 2006 | A1 |
| 20060173397 | Tu et al. | Aug 2006 | A1 |
| 20060173399 | Rodgers et al. | Aug 2006 | A1 |
| 20060178674 | McIntyre | Aug 2006 | A1 |
| 20060189915 | Camras et al. | Aug 2006 | A1 |
| 20060189916 | Bas et al. | Aug 2006 | A1 |
| 20060189917 | Mayr et al. | Aug 2006 | A1 |
| 20060195055 | Bergheim et al. | Aug 2006 | A1 |
| 20060195056 | Bergheim et al. | Aug 2006 | A1 |
| 20060195187 | Stegmann et al. | Aug 2006 | A1 |
| 20060200113 | Haffner et al. | Sep 2006 | A1 |
| 20060224146 | Lin | Oct 2006 | A1 |
| 20060241749 | Tu et al. | Oct 2006 | A1 |
| 20060259021 | Lin | Nov 2006 | A1 |
| 20060264971 | Akahoshi | Nov 2006 | A1 |
| 20060276759 | Kinast et al. | Dec 2006 | A1 |
| 20070010827 | Tu et al. | Jan 2007 | A1 |
| 20070021725 | Villette | Jan 2007 | A1 |
| 20070027452 | Varner et al. | Feb 2007 | A1 |
| 20070073275 | Conston et al. | Mar 2007 | A1 |
| 20070088432 | Solovay et al. | Apr 2007 | A1 |
| 20070093794 | Wang et al. | Apr 2007 | A1 |
| 20070093796 | Raksi et al. | Apr 2007 | A1 |
| 20070106200 | Levy | May 2007 | A1 |
| 20070106236 | Coroneo | May 2007 | A1 |
| 20070112292 | Tu et al. | May 2007 | A1 |
| 20070118147 | Smedley et al. | May 2007 | A1 |
| 20070121120 | Schachar | May 2007 | A1 |
| 20070135681 | Chin et al. | Jun 2007 | A1 |
| 20070173791 | Raksi | Jul 2007 | A1 |
| 20070179520 | West | Aug 2007 | A1 |
| 20070191863 | De Juan, Jr. et al. | Aug 2007 | A1 |
| 20070202186 | Yamamoto et al. | Aug 2007 | A1 |
| 20070208325 | Kurtz | Sep 2007 | A1 |
| 20070219509 | Tashiro et al. | Sep 2007 | A1 |
| 20070219541 | Kurtz | Sep 2007 | A1 |
| 20070235543 | Zadoyan et al. | Oct 2007 | A1 |
| 20070236771 | Zadoyan et al. | Oct 2007 | A1 |
| 20070265582 | Kaplan et al. | Nov 2007 | A1 |
| 20070270945 | Kobayashi et al. | Nov 2007 | A1 |
| 20070276315 | Haffner et al. | Nov 2007 | A1 |
| 20070276316 | Haffner et al. | Nov 2007 | A1 |
| 20070282244 | Tu et al. | Dec 2007 | A1 |
| 20070282245 | Tu et al. | Dec 2007 | A1 |
| 20070293807 | Lynch et al. | Dec 2007 | A1 |
| 20070293872 | Peyman | Dec 2007 | A1 |
| 20070298068 | Badawi et al. | Dec 2007 | A1 |
| 20080015488 | Tu et al. | Jan 2008 | A1 |
| 20080027519 | Guerrero | Jan 2008 | A1 |
| 20080045878 | Bergheim et al. | Feb 2008 | A1 |
| 20080058704 | Hee et al. | Mar 2008 | A1 |
| 20080058777 | Kurtz et al. | Mar 2008 | A1 |
| 20080082088 | Kurtz et al. | Apr 2008 | A1 |
| 20080091224 | Griffis et al. | Apr 2008 | A1 |
| 20080119827 | Kurtz et al. | May 2008 | A1 |
| 20080228127 | Burns et al. | Sep 2008 | A1 |
| 20080278687 | Somani | Nov 2008 | A1 |
| 20080288082 | Deal | Nov 2008 | A1 |
| 20080312661 | Downer et al. | Dec 2008 | A1 |
| 20090005852 | Gittings et al. | Jan 2009 | A1 |
| 20090028953 | Yamamoto et al. | Jan 2009 | A1 |
| 20090030363 | Gellman | Jan 2009 | A1 |
| 20090030381 | Lind et al. | Jan 2009 | A1 |
| 20090036843 | Erskine | Feb 2009 | A1 |
| 20090043321 | Conston et al. | Feb 2009 | A1 |
| 20090054723 | Khairkhahan et al. | Feb 2009 | A1 |
| 20090069786 | Vesely et al. | Mar 2009 | A1 |
| 20090082862 | Schieber et al. | Mar 2009 | A1 |
| 20090104248 | Rapacki et al. | Apr 2009 | A1 |
| 20090118716 | Brownell | May 2009 | A1 |
| 20090118717 | Brownell et al. | May 2009 | A1 |
| 20090118718 | Raksi et al. | May 2009 | A1 |
| 20090131921 | Kurtz et al. | May 2009 | A1 |
| 20090137988 | Kurtz | May 2009 | A1 |
| 20090138081 | Bergheim et al. | May 2009 | A1 |
| 20090157062 | Hauger et al. | Jun 2009 | A1 |
| 20090171327 | Kurtz et al. | Jul 2009 | A1 |
| 20090182421 | Silvestrini et al. | Jul 2009 | A1 |
| 20090198248 | Yeung et al. | Aug 2009 | A1 |
| 20090204053 | Nissan et al. | Aug 2009 | A1 |
| 20090247955 | Yamamoto et al. | Oct 2009 | A1 |
| 20090259126 | Saal et al. | Oct 2009 | A1 |
| 20090281520 | Highley et al. | Nov 2009 | A1 |
| 20090281530 | Korn | Nov 2009 | A1 |
| 20090291423 | Hara | Nov 2009 | A1 |
| 20100004580 | Lynch et al. | Jan 2010 | A1 |
| 20100036488 | de Juan et al. | Feb 2010 | A1 |
| 20100057072 | Roman et al. | Mar 2010 | A1 |
| 20100114309 | de Juan et al. | May 2010 | A1 |
| 20100137981 | Silvestrini et al. | Jun 2010 | A1 |
| 20100173866 | Hee et al. | Jul 2010 | A1 |
| 20100191176 | Ho et al. | Jul 2010 | A1 |
| 20100191177 | Chang et al. | Jul 2010 | A1 |
| 20100234726 | Sirimanne et al. | Sep 2010 | A1 |
| 20100234790 | Tu et al. | Sep 2010 | A1 |
| 20100262174 | Sretavan et al. | Oct 2010 | A1 |
| 20100324543 | Kurtz et al. | Dec 2010 | A1 |
| 20100331858 | Simaan et al. | Dec 2010 | A1 |
| 20110028948 | Raksi et al. | Feb 2011 | A1 |
| 20110028949 | Raksi et al. | Feb 2011 | A1 |
| 20110028950 | Raksi et al. | Feb 2011 | A1 |
| 20110028951 | Raksi et al. | Feb 2011 | A1 |
| 20110028952 | Raksi et al. | Feb 2011 | A1 |
| 20110028953 | Raksi et al. | Feb 2011 | A1 |
| 20110028954 | Raksi et al. | Feb 2011 | A1 |
| 20110028955 | Raksi | Feb 2011 | A1 |
| 20110028957 | Raksi et al. | Feb 2011 | A1 |
| 20110028958 | Raksi et al. | Feb 2011 | A1 |
| 20110098809 | Wardle et al. | Apr 2011 | A1 |
| 20110196487 | Badawi et al. | Aug 2011 | A1 |
| 20110218523 | Robl | Sep 2011 | A1 |
| 20110224597 | Stegmann et al. | Sep 2011 | A1 |
| 20120010702 | Stegmann et al. | Jan 2012 | A1 |
| 20120021397 | Van Dalen et al. | Jan 2012 | A1 |
| 20120022424 | Yamamoto et al. | Jan 2012 | A1 |
| 20120035524 | Silvestrini | Feb 2012 | A1 |
| 20120191064 | Conston et al. | Jul 2012 | A1 |
| 20120271272 | Hammack et al. | Oct 2012 | A1 |
| 20120283557 | Berlin | Nov 2012 | A1 |
| 20120302861 | Marshall et al. | Nov 2012 | A1 |
| 20130023837 | Becker | Jan 2013 | A1 |
| 20130182223 | Wardle et al. | Jul 2013 | A1 |
| 20130184631 | Pinchuk | Jul 2013 | A1 |
| 20130253402 | Badawi et al. | Sep 2013 | A1 |
| 20130253403 | Badawi et al. | Sep 2013 | A1 |
| 20130253437 | Badawi et al. | Sep 2013 | A1 |
| 20130253438 | Badawi et al. | Sep 2013 | A1 |
| 20130253528 | Haffner et al. | Sep 2013 | A1 |
| 20130267887 | Kahook et al. | Oct 2013 | A1 |
| 20130281908 | Schaller et al. | Oct 2013 | A1 |
| 20140018720 | Horvath et al. | Jan 2014 | A1 |
| 20140066821 | Friedland et al. | Mar 2014 | A1 |
| 20140066831 | Silvestrini et al. | Mar 2014 | A1 |
| 20140081195 | Clauson et al. | Mar 2014 | A1 |
| 20150018746 | Hattenbach | Jan 2015 | A1 |
| 20150022780 | John et al. | Jan 2015 | A1 |
| 20150038893 | Haffner et al. | Feb 2015 | A1 |
| 20150045714 | Horvath et al. | Feb 2015 | A1 |
| 20150057583 | Gunn et al. | Feb 2015 | A1 |
| 20150057591 | Horvath et al. | Feb 2015 | A1 |
| 20150065940 | Rangel-Friedman et al. | Mar 2015 | A1 |
| 20150148836 | Heeren | May 2015 | A1 |
| 20150282982 | Schieber et al. | Oct 2015 | A1 |
| 20150290033 | Wardle et al. | Oct 2015 | A1 |
| 20150305939 | Vera et al. | Oct 2015 | A1 |
| 20150305940 | Vera et al. | Oct 2015 | A1 |
| 20150313759 | Vera et al. | Nov 2015 | A1 |
| 20150366710 | Schieber et al. | Dec 2015 | A1 |
| 20160051406 | Wardle et al. | Feb 2016 | A1 |
| 20160063898 | Bernal | Mar 2016 | A1 |
| 20160250072 | Wardle et al. | Sep 2016 | A1 |
| 20170127941 | Ostermeier et al. | May 2017 | A1 |
| 20170143541 | Badawi et al. | May 2017 | A1 |
| 20170156848 | Schieber | Jun 2017 | A1 |
| 20170164831 | Choo et al. | Jun 2017 | A1 |
| 20170172794 | Varner et al. | Jun 2017 | A1 |
| 20170172795 | Lerner | Jun 2017 | A1 |
| 20170172797 | Horvath et al. | Jun 2017 | A1 |
| 20170172798 | Horvath et al. | Jun 2017 | A1 |
| 20170172799 | Horvath | Jun 2017 | A1 |
| 20170172800 | Romoda et al. | Jun 2017 | A1 |
| 20170202708 | Berlin | Jul 2017 | A1 |
| 20170239272 | Ambati et al. | Aug 2017 | A1 |
| 20170251921 | Phan et al. | Sep 2017 | A1 |
| 20170252212 | Eutenuer et al. | Sep 2017 | A1 |
| 20170280997 | Lai et al. | Oct 2017 | A1 |
| 20170281409 | Haffner et al. | Oct 2017 | A1 |
| 20170290705 | Wardle et al. | Oct 2017 | A1 |
| 20170348150 | Horvath et al. | Dec 2017 | A1 |
| 20170360609 | Schieber et al. | Dec 2017 | A9 |
| 20180221205 | Berlin | Aug 2018 | A1 |
| 20190343679 | Wardle et al. | Nov 2019 | A1 |
| 20190380874 | Schieber et al. | Dec 2019 | A1 |
| 20200085620 | Euteneuer et al. | Mar 2020 | A1 |
| 20200197221 | Schieber et al. | Jun 2020 | A1 |
| 20200261270 | Berlin | Aug 2020 | A1 |
| 20210030590 | Blanda et al. | Feb 2021 | A1 |
| 20210330499 | Wardle et al. | Oct 2021 | A1 |
| 20210361479 | Wardle et al. | Nov 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 199876197 | Feb 1999 | AU |
| 4226476 | Aug 1993 | DE |
| 102012221350 | May 2014 | DE |
| 0168201 | Jun 1988 | EP |
| 0957949 | Nov 1996 | EP |
| 0766544 | May 1998 | EP |
| 1615604 | Aug 2009 | EP |
| 2193821 | Jun 2010 | EP |
| 1715827 | Dec 2010 | EP |
| 2380622 | Oct 2011 | EP |
| 2468327 | Jun 2012 | EP |
| 2471563 | Jul 2012 | EP |
| 1833440 | Aug 2012 | EP |
| 3164061 | May 2017 | EP |
| 2996648 | Jun 2017 | EP |
| 1732484 | Aug 2017 | EP |
| 1740153 | Aug 2017 | EP |
| 3076948 | Aug 2017 | EP |
| 3205333 | Aug 2017 | EP |
| 3060180 | Sep 2017 | EP |
| 3082570 | Sep 2017 | EP |
| 10504978 | May 1998 | JP |
| 11123205 | May 1999 | JP |
| 2002542872 | Dec 2002 | JP |
| 2006517848 | Aug 2006 | JP |
| 2006289075 | Oct 2006 | JP |
| 2009523545 | Jun 2009 | JP |
| 2010509003 | Mar 2010 | JP |
| 2011502649 | Jan 2011 | JP |
| 2012527318 | Nov 2012 | JP |
| 2015517836 | Jun 2015 | JP |
| 2017517363 | Jun 2017 | JP |
| WO9620742 | Jul 1996 | WO |
| WO9901063 | Jan 1999 | WO |
| WO9945868 | Sep 1999 | WO |
| WO0007525 | Feb 2000 | WO |
| WO0013627 | Mar 2000 | WO |
| WO0064389 | Nov 2000 | WO |
| WO0064393 | Nov 2000 | WO |
| WO0067687 | Nov 2000 | WO |
| WO0189437 | Nov 2001 | WO |
| WO0197727 | Dec 2001 | WO |
| WO0236052 | May 2002 | WO |
| WO02074052 | Sep 2002 | WO |
| WO02080811 | Oct 2002 | WO |
| WO03015659 | Feb 2003 | WO |
| WO03045290 | Jun 2003 | WO |
| WO2004054643 | Jul 2004 | WO |
| WO2004093761 | Nov 2004 | WO |
| WO2005105197 | Nov 2005 | WO |
| WO2006066103 | Jun 2006 | WO |
| WO2007035356 | Mar 2007 | WO |
| WO2007047744 | Apr 2007 | WO |
| WO2007087061 | Aug 2007 | WO |
| WO2008002377 | Jan 2008 | WO |
| WO2008005873 | Jan 2008 | WO |
| WO2009120960 | Oct 2009 | WO |
| WO2011053512 | May 2011 | WO |
| WO2011057283 | May 2011 | WO |
| WO2011106781 | Sep 2011 | WO |
| WO2011150045 | Dec 2011 | WO |
| WO2012051575 | Apr 2012 | WO |
| WO2012083143 | Jun 2012 | WO |
| WO2013147978 | Oct 2013 | WO |
| WO2016154066 | Sep 2016 | WO |
| WO2017030902 | Feb 2017 | WO |
| WO2017030917 | Feb 2017 | WO |
| WO2017062347 | Apr 2017 | WO |
| WO2017087713 | May 2017 | WO |
| WO2017095825 | Jun 2017 | WO |
| WO2017132418 | Aug 2017 | WO |
| WO2017132647 | Aug 2017 | WO |
| WO2017156530 | Sep 2017 | WO |
| Entry |
|---|
| Ha D, de Vries W N, John S W, Irazoqui P P, Chappell W J (2012) Polymer-based miniature flexible capacitive pressure sensor for intraocular pressure (IOP) monitoring inside a mouse eye. Biomed Microdevices 14:207-15. PMID: 21096710 (Year: 2012). |
| Sugiyama et al.; Micro-Diaphragm Pressure Sensor; 1986 International Electron Devices Meeting; pp. 184-187; Dec. 7, 1986. |
| Berlin; U.S. Appl. No. 16/525,267 entitled “Delivery system and method of use for the eye,” filed Jul. 29, 2019. |
| Wardle et al.; U.S. Appl. No. 16/668,458 entitled “Single operator device for delivering an ocular implant,” filed Oct. 30, 2019. |
| Bahler, et al.; Trabecular bypass stents decrease intraocular pressure in cultured human anterior segments; Amer. Journal of Ophthalmology; vol. 138, No. 6; pp. 988-994.e2; Dec. 2004. |
| Berlin et al.; U.S. Appl. No. 15/868,904 entitled Methods and systems for OCT guided glaucoma surgery, filed Jan. 11, 2018. |
| Cambridge Dictionary; Sensor (definition); 2 pages; retrived from the internet (http://dictionary.cambridge.org/define.asp?dict=CALD&key=71811 >) on Aug. 14, 2018. |
| Camras et al.; A novel schlemm's canal scaffold increases outflow facility in a human anterior segment perfusion model; Invest. Opthalmol. Vis. Sci. ; 53(10); pp. 6115-6121; Sep. 1, 2012. |
| D'Ermo, et al.; Our results with the operation of ab externo trabeculotomy; Ophthalmologica; vol. 163; pp. 347-355; Feb. 1971. |
| Dietlein et al.; Morphological variability of the trabecular meshwork in glaucoma patients: implications for non-perforating glaucoma surgery; British Journal of Ophthalmology; 84(12); pp. 1354-1359; Dec. 2000. |
| Ellingsen et al.; Trabeculotomy and sinusotomy in enucleated human eyes; Investigative Ophthalmology; vol. 11; pp. 21-28; Jan. 1972. |
| Grant; Experimental aqueous perfusion in enucleated human eyes; Archives of Ophthalmology; vol. 69; pp. 783-801; Jun. 1963. |
| Gulati et al.; A novel 8-mm schlemm's canal scaffold reduces outflow resistance in a human anterior segment perfusion model; Invest. Ophthalmol. Vis. Sci .; 54(3); pp. 1698-1704; Mar. 5, 2013. |
| Hays et al.; Improvement in outflow facility by two novel microinvasive glaucoma surgery implants; Invest. Ophthalmol. Vis. Sci.; 55(3); pp. 1893-1900; Mar. 1, 2014. |
| Huang et al.; Optical coherence tomography; Science; 254(5035); pp. 1178-1181; 12 pages (Author Manuscript); Nov. 1991. |
| Johnstone et al.; “Microsurgery of Schlemm's Canal and the Human Aqueous Outflow System;” American Journal of Ophthalmology, vol. 76 (6): 906-917; Dec. 1973. |
| Johnstone et al.; Effects of a schlemm canal scaffold on collector channel ostia in human anterior segments; Exp. Eye. Res .; 119; pp. 70-76; Feb. 2014. |
| Johnstone; Aqueous humor outflow system overview; Becker-Shaffer's Diagnosis and Therapy of the Glaucomas; Part 2 Aqueous Humor Dynamics; Chapter 3; pp. 25-46; Mosby Elseveir; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2009. |
| Kirkness et al.; The Use of Silicone Drainage Tubing to Control Post-Keratoplasty Glaucoma; Eye; 2 (pt 5); pp. 583-590; Apr. 1988. |
| Lee et al.; Aqueous-venous shunt and intraocular pressure. Preliminary report of animal studies; Investigative Ophthalmology; vol. 5; No. 1; pp. 59-64; Feb. 1966. |
| Lee et al.; Short-pulsed neodymium-YAG laser trabeculotomy. An in vivo morphological study in the human eye; Investigative Ophthalmology and Visual Science; 29(11); pp. 1698-1707; Nov. 1988. |
| Lynch, Mary G.; U.S. Appl. No. 60/131,030 entitled “Devices and methods for treating glaucoma by enhancing aqueous outflow through schlemm's canal and anterior chamber angle,” filed Apr. 26, 1999. |
| Macmilla Online Dictionary; Detector (definition); Macmilla On Line Dictionary; 2 pages; retrived from the internet (https://www.macmillandictionary.com/dictionary/british/detector) on Aug. 14, 2018. |
| Mäepea et al.; The pressures in the episcleral veins, schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure; Exp. Eye Res.; vol. 49; pp. 645-663; Oct. 1989. |
| Molteno et al.; Long Tube Implants in the Management of Glaucoma; SA Medical Journal; 26; pp. 1062-1066; Jun. 1976. |
| Molteno; New implant for drainage in glaucoma; Brit. J. Ophthal; 53; pp. 606-615; Sep. 1969. |
| Moses, Robert; The effect of intraocular pressure on resistance to outflow; Survey of Ophthalmology; vol. 22; No. 2; pp. 88-100; Sep.-Oct. 1977. |
| Nakamura et al.; Femtosecond laser photodisruption of primate trabecular meshwork: an ex vivo study; Investigative Ophthalmology and Visual Science; 50(3); pp. 1198-1204; Mar. 2009. |
| Owen; A moving-mirror gonioscope for retinal surgery; British Journal of Ophthalmology; 61(3); pp. 246-247; Mar. 1977. |
| Oxford Dictionaries; Detector (definition); 1 page; retrieved from the internet (https://en.oxforddictionaries.com/definition/detector) on Aug. 14, 2018. |
| Oxford Dictionaries; Sensor (definition); 1 page; retrieved from te internet (http://www.askoxford.com/concise_oed/sensor?view=uk>) on Aug. 14, 2018. |
| Radhakrishnan et al.; Real-time optical coherence tomography of the anterior segment at 1310 nm; Archives of Opthhalmology; 119(8); pp. 1179-1185; Aug. 2001. |
| Rosenquist et al.; Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy; Current Eye Res.; vol. 8; No. 12; pp. 1233-1240; Dec. 1989. |
| Savage, James; Gonioscopy in the management of glaucoma; Am. Academy of Ophthalmology; Focal Points; vol. XXIV; No. 3; pp. 1-14; Mar. 2006. |
| Schocket et al.; Anterior Chamber Tube Shunt to an Encircling Band in the Treatment of Neovascular Glaucoma and other Refractory Glaucomas; Ophthalmology; 92; pp. 553-562; Apr. 1985. |
| Schultz, Jared; Canaloplasty procedure shows promise for open-angle glaucoma in European study; Ocular Surgery News; vol. 34; Mar. 1, 2007. |
| Smit et al.; Effects of viscoelastic injection into schlemm's canal in primate and human eyes; J. Am. Academy of Ophthalmology; vol. 109; No. 4; pp. 786-792; Apr. 2002. |
| Spiegel et al.; Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG ?; Ophthalmic Surgery and Lasers; vol. 30; No. 6; pp. 492-494; Jun. 1999. |
| Toyran et al.; Femtosecond laser photodisruption of human trabecular meshwork: an in vitro study; Experimental Eye Research; 81(3); pp. 298-305; Sep. 2005. |
| Wilcox et al.; Hypothesis for Improving Accessory Filtration by Using Geometry; Journal of Glaucoma; 3; pp. 244-247; Fall 1994. |
| Yuan et al.; Mathematical modeling of outflow facility increase with trabecular meshwork bypass and schlemm canal dilation; J. Glaucoma; 10 pgs.; Mar. 24, 2015 (Epub ahead of print). |
| Van Meter et al.; U.S. Appl. No. 15/751,886 entitled “Ocular implant with pressure sensor and delivery system,” filed Feb. 12, 2018. |
| Schieber et al.; U.S. Appl. No. 16/828,054 entitled “Methods and devices for increasing aqueous humor outflow,” filed Mar. 24, 2020. |
| Berlin; U.S. Appl. No. 16/196,260 entitled “Delivery system and method of use for the eye,” filed Nov. 20, 2018. |
| Van Meter et al.; U.S. Appl. No. 17/620,456 entitled “Ocular implant with pressure sensor and delivery system,” filed Nov. 5, 2021. |
| Wardle et al.; U.S. Appl. No. 17/548,212 entitled “Single operator device for delivering an ocular implant,” filed Dec. 10, 2021. |
| Number | Date | Country | |
|---|---|---|---|
| 20180369017 A1 | Dec 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62267794 | Dec 2015 | US |
